BR112012008315A2 - terapia de câncer resistente a fármaco e alvejada com célula-tronco de câncer - Google Patents

terapia de câncer resistente a fármaco e alvejada com célula-tronco de câncer

Info

Publication number
BR112012008315A2
BR112012008315A2 BR112012008315A BR112012008315A BR112012008315A2 BR 112012008315 A2 BR112012008315 A2 BR 112012008315A2 BR 112012008315 A BR112012008315 A BR 112012008315A BR 112012008315 A BR112012008315 A BR 112012008315A BR 112012008315 A2 BR112012008315 A2 BR 112012008315A2
Authority
BR
Brazil
Prior art keywords
stem cell
drug resistant
therapy targeted
cancer
cancer therapy
Prior art date
Application number
BR112012008315A
Other languages
English (en)
Other versions
BR112012008315B1 (pt
Inventor
Angelika Burger
Original Assignee
Kominox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kominox Inc filed Critical Kominox Inc
Publication of BR112012008315A2 publication Critical patent/BR112012008315A2/pt
Publication of BR112012008315B1 publication Critical patent/BR112012008315B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/36Arsenic; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112012008315-5A 2009-09-10 2010-09-09 Uso de um agente terapêutico para o tratamento de câncer de próstata resistente ao paclitaxel ou docitaxel BR112012008315B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24118009P 2009-09-10 2009-09-10
US61/241,180 2009-09-10
PCT/US2010/048308 WO2011031890A2 (en) 2009-09-10 2010-09-09 Cancer stem cell-targeted and drug resistant cancer therapy

Publications (2)

Publication Number Publication Date
BR112012008315A2 true BR112012008315A2 (pt) 2016-09-13
BR112012008315B1 BR112012008315B1 (pt) 2021-08-03

Family

ID=43647965

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012008315-5A BR112012008315B1 (pt) 2009-09-10 2010-09-09 Uso de um agente terapêutico para o tratamento de câncer de próstata resistente ao paclitaxel ou docitaxel

Country Status (24)

Country Link
US (1) US20110059186A1 (pt)
EP (1) EP2475362B1 (pt)
JP (1) JP5710619B2 (pt)
KR (2) KR20120061908A (pt)
CN (2) CN102753164A (pt)
AR (1) AR079000A1 (pt)
AU (1) AU2010292192B2 (pt)
BR (1) BR112012008315B1 (pt)
CA (1) CA2772411C (pt)
CY (1) CY1121973T1 (pt)
DK (1) DK2475362T3 (pt)
ES (1) ES2723778T3 (pt)
HU (1) HUE043387T2 (pt)
IN (1) IN2012DN02008A (pt)
LT (1) LT2475362T (pt)
MX (1) MX2012002855A (pt)
PL (1) PL2475362T3 (pt)
PT (1) PT2475362T (pt)
RU (1) RU2568834C2 (pt)
SG (2) SG179069A1 (pt)
SI (1) SI2475362T1 (pt)
TR (1) TR201905548T4 (pt)
TW (1) TWI564012B (pt)
WO (1) WO2011031890A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US20120251628A1 (en) * 2011-03-30 2012-10-04 Young Joo Min Compositions and methods for treatment of cancer
US9963701B2 (en) 2013-09-30 2018-05-08 Korea Institute Of Radiological & Medical Sciences Pharmaceutical composition for treatment of radiation- or drug-resistant cancer comprising HRP-3 inhibitor
WO2017165675A1 (en) * 2016-03-24 2017-09-28 The Board Of Regents Of The University Of Texas System Treatment of drug resistant proliferative diseases with telomerase mediated telomere altering compounds
EP3634494A4 (en) * 2017-05-24 2021-03-17 The Regents of the University of California ANTISENSE THERAPIES TO TREAT CANCER
TWI749414B (zh) * 2019-11-29 2021-12-11 高雄醫學大學 細胞學抹片影像自動分析及診察結果自動批改方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441050A (en) 1992-12-18 1995-08-15 Neoprobe Corporation Radiation responsive surgical instrument
DE69434093T2 (de) * 1994-02-18 2006-03-09 Tamara Vasilievna Vorobieva Substanz mit immunonodulierender wirkung und zur verringerung der disfunktion des gewebezellenregelungssystems
US5362735A (en) * 1994-02-23 1994-11-08 Smithkline Beecham Corporation Rapamycin derivatives
ATE409043T1 (de) * 1997-10-15 2008-10-15 Polarx Biopharmaceuticals Inc Pharmazeutische zusammensetzungen enthaltend arsentrioxid zur behandlung von krebs des zentralen nervensystems
EP1037625A4 (en) * 1997-11-10 2002-07-31 Sloan Kettering Inst Cancer PROCESS FOR PRODUCING ARSENIC TRIOXIDE FORMULATIONS AND METHODS OF CANCER THERAPY USING ARSENIC TRIOXIDE OR MELARSOPROL
CN1233476A (zh) * 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
US6262070B1 (en) * 1998-11-04 2001-07-17 Darwin Discovery Ltd. Heterocyclic compounds and their therapeutic use
TW200408407A (en) * 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
EP2042182B1 (en) * 2002-04-10 2013-05-22 Komipharm International Co., Ltd. Pharmaceutical composition comprising arsenite for the treatment of malignancy
WO2006104292A1 (en) * 2005-03-31 2006-10-05 Komipharm International Co., Ltd. Pharmaceutical composition comprising arsenic acid, meta-arsenite, and pharmaceutically acceptable salts
EP1721615A1 (en) * 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US20060292243A1 (en) * 2005-06-24 2006-12-28 Shao-Chi Hsin Arsenic compounds for the treatment of the arsenic-sensitive blast-cell related diseases
US8945505B2 (en) * 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
US20080279961A1 (en) * 2007-05-11 2008-11-13 Burger Angelika M Telomere targeting agents as stem cells directed treatments
US20090246291A1 (en) * 2008-03-27 2009-10-01 Angelika Burger Method and compositions for treatment of cancer
BR112012008310A2 (pt) * 2009-09-18 2017-06-06 Kominox Inc métodos para tratamento de tumores cerebrais

Also Published As

Publication number Publication date
AR079000A1 (es) 2011-12-21
IN2012DN02008A (pt) 2015-07-24
LT2475362T (lt) 2019-06-10
EP2475362A4 (en) 2013-03-27
EP2475362A2 (en) 2012-07-18
RU2012108144A (ru) 2013-10-20
EP2475362B1 (en) 2019-03-27
RU2568834C2 (ru) 2015-11-20
PT2475362T (pt) 2019-05-27
CA2772411A1 (en) 2011-03-17
AU2010292192B2 (en) 2015-04-02
KR20120061908A (ko) 2012-06-13
CN107412771A (zh) 2017-12-01
PL2475362T3 (pl) 2019-09-30
JP5710619B2 (ja) 2015-04-30
HUE043387T2 (hu) 2019-08-28
KR101721009B1 (ko) 2017-03-29
MX2012002855A (es) 2012-07-20
TWI564012B (zh) 2017-01-01
DK2475362T3 (da) 2019-06-03
JP2013504587A (ja) 2013-02-07
US20110059186A1 (en) 2011-03-10
CA2772411C (en) 2017-08-22
TW201114430A (en) 2011-05-01
KR20150038702A (ko) 2015-04-08
CN102753164A (zh) 2012-10-24
SG10201608967WA (en) 2016-12-29
ES2723778T3 (es) 2019-09-02
WO2011031890A2 (en) 2011-03-17
SI2475362T1 (sl) 2019-08-30
WO2011031890A3 (en) 2011-08-25
TR201905548T4 (tr) 2019-05-21
SG179069A1 (en) 2012-04-27
BR112012008315B1 (pt) 2021-08-03
AU2010292192A1 (en) 2012-03-29
WO2011031890A4 (en) 2011-10-13
CY1121973T1 (el) 2020-10-14

Similar Documents

Publication Publication Date Title
BRPI1008955A2 (pt) Terapia de combinação com derivados de tiocolchicina.
EP2318040A4 (en) THERAPY TREATED ON CANCER STAMPS
BRPI1009454A2 (pt) vacinas contra o câncer direcionadas a células apresentadoras de antígenos
SMT201500177B (it) Combinazione terapeutica comprendente dolutegravir, abacavir e lamivudina
BRPI0924549A2 (pt) nano fotomedicamentos como alvo para terapia fotodinâmica do câncer
BR112012005594A2 (pt) tratamento de câncer
DK2475294T3 (da) Implanterbar sensor
DK2396072T3 (da) Stimulerende elektrode-leveringssystem
IL218523A0 (en) Extracellular targeted drug conjugates
BRPI1006438A2 (pt) terapia adjuvante de cancer
BR112012002797A2 (pt) tratamento de câncer de próstata
BRPI0821248A2 (pt) Inibidores de cinesina como fármacos terapêuticos para câncer
DK2219683T3 (da) Målrettet radioterapi
BRPI1008664A2 (pt) comprimidos para a terapia de combinação
BRPI0910534A2 (pt) terapia antiviral
EP2575887A4 (en) CONJUGATES OF OPTIMIZED MEDICINES
DK2437736T3 (da) Lægemiddelindgivelsessystemer
BRPI0925056A2 (pt) medicamento mastigável
BRPI0922832A2 (pt) nonapeptídeo com atividade antitumor
BR112012008315A2 (pt) terapia de câncer resistente a fármaco e alvejada com célula-tronco de câncer
BRPI0920743A2 (pt) ribonucleases terapeuticas
BRPI1013903A2 (pt) tratamentos terapêuticos utilizando centaquina
EP2473613A4 (en) KREBSAUSHUNGERUNGSTHERAPIE
BRPI0807654A2 (pt) Terapia com vacinas para a neovascularização de coroide
BR112013014445A2 (pt) injetor de tubulação com redundância embutida

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/09/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.